HDAC inhibition elicits myocardial protective effect through modulation of MKK3/Akt-1

Ting C Zhao1, Jianfeng Du, Shougang Zhuang

  • 1Cardiovascular Research laboratory, Department of Surgery, Roger Williams Medical Center, Boston University Medical School, Providence, Rhode Island, United States of America. tzhao@bu.edu

Plos One
|June 14, 2013
PubMed

Insights

Histone deacetylase (HDAC) inhibition protects the heart. This study shows that MKK3 and Akt-1 pathways are crucial for HDAC inhibition-induced cardioprotection against ischemia-reperfusion injury.

Area of Science:

  • Cardiovascular Biology
  • Molecular Cardiology
  • Pharmacology

Background:

  • Histone deacetylase (HDAC) inhibition is known to protect the heart from injury.
  • Akt-1 and MAP kinase are critical for myocardial protection and cardiac preconditioning.
  • Previous work showed Akt-1 activation post-myocardial infarction following HDAC inhibition.

Purpose of the Study:

  • To investigate if MKK3 and Akt-1 are involved in HDAC inhibition-induced cardioprotection during acute myocardial ischemia and reperfusion.
  • To determine if genetic disruption of Akt-1 and MKK3 eliminates HDAC inhibition-induced cardioprotection.
  • To explore the association between Akt-1 and MKK3 in achieving protective effects.

Main Methods:

  • Adult wild-type, MKK3 knockout, and Akt-1 knockout mice were used.
  • Pharmacologic preconditioning was induced using trichostatin A (HDAC inhibitor).
  • Hearts underwent ischemia/reperfusion injury; left ventricular function and infarct size were assessed.

Main Results:

  • HDAC inhibition improved left ventricular functional recovery and reduced infarct size.
  • Disruption of Akt-1 or MKK3 abrogated these protective effects.
  • Akt-1 disruption abolished MKK3 acetylation and phosphorylation; Trichostatin A increased MKK3 phosphorylation/acetylation.

Conclusions:

  • The MKK3 and Akt-1 pathway is essential for HDAC inhibition-induced cardioprotection.
  • Targeting the MKK3-Akt-1 pathway represents a novel strategy for mitigating myocardial injury.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...